Diabetes & Metabolism Journal

Response

Response: Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study (Diabetes Metab J 2019;43:521-9): Jun Namkung, Kyu-Sang Park; Diabetes Metab J. 2019;43(5):729-730. Published online October 24, 2019; DOI: https://doi.org/10.4093/dmj.2019.0178

2,738 View
34 Download

PDF PubReader

Original Articles

Obesity and Metabolic Syndrome
Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study: Jun Namkung, Joon Hyung Sohn, Jae Seung Chang, Sang-Wook Park, Jang-Young Kim, Sang-Baek Koh, In Deok Kong, Kyu-Sang Park; Diabetes Metab J. 2019;43(4):521-529. Published online March 29, 2019; DOI: https://doi.org/10.4093/dmj.2018.0080

4,742 View
51 Download
15 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome.

Methods

In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations.

Results

During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, P=0.001). In the multivariable adjusted models, the odds ratio for the development of metabolic syndrome in the highest quartile of ANGPTL6 levels was 3.61 (95% confidence interval, 1.27 to 10.26). The use of ANGPTL6 levels in addition to the conventional components improved the prediction of new-onset metabolic syndrome (area under the receiver operating characteristic curve: 0.775 vs. 0.807, P=0.036).

Conclusion

Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.

Citations

Citations to this article as recorded by

Angiopoietin-Like Proteins: Cardiovascular Biology and Therapeutic Targeting for the Prevention of Cardiovascular Diseases
Eric Thorin, Pauline Labbé, Mélanie Lambert, Pauline Mury, Olina Dagher, Géraldine Miquel, Nathalie Thorin-Trescases
Canadian Journal of Cardiology.2023; 39(12): 1736. CrossRef
Hyperlipidemia and hypothyroidism
Xin Su, Hua Peng, Xiang Chen, Xijie Wu, Bin Wang
Clinica Chimica Acta.2022; 527: 61. CrossRef
Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease
Eunha Chang, Jae Seung Chang, In Deok Kong, Soon Koo Baik, Moon Young Kim, Kyu-Sang Park
Gut and Liver.2022; 16(2): 171. CrossRef
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Bai-Hui Zhang, Fan Yin, Ya-Nan Qiao, Shou-Dong Guo
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Relationship of ANGPTL6 With Neonatal Glucose Homeostasis and Fat Mass Is Disrupted in Gestational Diabetic Pregnancies
Abel Valencia-Martínez, Ute Schaefer-Graf, Encarnación Amusquivar, Emilio Herrera, Henar Ortega-Senovilla
The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4078. CrossRef
Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism
Huixing Liu, Daoquan Peng
Endocrine Connections.2022;[Epub] CrossRef
RETRACTED ARTICLE: Relationship between the development of hyperlipidemia in hypothyroidism patients
Xin Su, Xiang Chen, Bin Wang
Molecular Biology Reports.2022; 49(11): 11025. CrossRef
Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial
Jae Seung Chang, Jun Namkung
International Journal of Environmental Research and Public Health.2021; 18(5): 2242. CrossRef
Angiopoietin-like proteins in atherosclerosis
Yi-Zhang Liu, Chi Zhang, Jie-Feng Jiang, Zhe-Bin Cheng, Zheng-Yang Zhou, Mu-Yao Tang, Jia-Xiang Sun, Liang Huang
Clinica Chimica Acta.2021; 521: 19. CrossRef
Effects of Bariatric Surgeries on Fetuin-A, Selenoprotein P, Angiopoietin-Like Protein 6, and Fibroblast Growth Factor 21 Concentration
Jakub Poloczek, Wojciech Kazura, Ewa Kwaśnicka, Janusz Gumprecht, Jerzy Jochem, Dominika Stygar, Munmun Chattopadhyay
Journal of Diabetes Research.2021; 2021: 1. CrossRef
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
Tae Hyun Kim, Dong-Gyun Hong, Yoon Mee Yang
Biomedicines.2021; 9(12): 1903. CrossRef
Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis
Semra ÖZKAN ÖZTÜRK, Hilmi ATASEVEN
Cumhuriyet Medical Journal.2021;[Epub] CrossRef
ANGPTL6 Level in Patient with Coronary Heart Disease and Its Relationship with the Severity of Coronary Artery Lesions
蕾任
Advances in Clinical Medicine.2020; 10(05): 714. CrossRef
Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes
Mohammad G. Qaddoumi, Muath Alanbaei, Maha M. Hammad, Irina Al Khairi, Preethi Cherian, Arshad Channanath, Thangavel Alphonse Thanaraj, Fahd Al-Mulla, Mohamed Abu-Farha, Jehad Abubaker
Scientific Reports.2020;[Epub] CrossRef
Letter: Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study (Diabetes Metab J 2019;43:521-9)
Jin Hwa Kim
Diabetes & Metabolism Journal.2019; 43(5): 727. CrossRef
Response: Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study (Diabetes Metab J 2019;43:521-9)
Jun Namkung, Kyu-Sang Park
Diabetes & Metabolism Journal.2019; 43(5): 729. CrossRef

Obesity and Metabolic Syndrome
Inhibition of Serotonin Synthesis Induces Negative Hepatic Lipid Balance: Jun Namkung, Ko Eun Shong, Hyeongseok Kim, Chang-Myung Oh, Sangkyu Park, Hail Kim; Diabetes Metab J. 2018;42(3):233-243. Published online April 25, 2018; DOI: https://doi.org/10.4093/dmj.2017.0084

4,708 View
84 Download
24 Web of Science
22 Crossref

Abstract PDF PubReader

Background

Hepatic steatosis is caused by metabolic stress associated with a positive lipid balance, such as insulin resistance and obesity. Previously we have shown the anti-obesity effects of inhibiting serotonin synthesis, which eventually improved insulin sensitivity and hepatic steatosis. However, it is not clear whether serotonin has direct effect on hepatic lipid accumulation. Here, we showed the possibility of direct action of serotonin on hepatic steatosis.

Methods

Mice were treated with para-chlorophenylalanine (PCPA) or LP-533401 to inhibit serotonin synthesis and fed with high fat diet (HFD) or high carbohydrate diet (HCD) to induce hepatic steatosis. Hepatic triglyceride content and gene expression profiles were analyzed.

Results

Pharmacological and genetic inhibition of serotonin synthesis reduced HFD-induced hepatic lipid accumulation. Furthermore, short-term PCPA treatment prevented HCD-induced hepatic steatosis without affecting glucose tolerance and browning of subcutaneous adipose tissue. Gene expression analysis revealed that the expressions of genes involved in de novo lipogenesis and triacylglycerol synthesis were downregulated by short-term PCPA treatment as well as long-term PCPA treatment.

Conclusion

Short-term inhibition of serotonin synthesis prevented hepatic lipid accumulation without affecting systemic insulin sensitivity and energy expenditure, suggesting the direct steatogenic effect of serotonin in liver.

Citations

Citations to this article as recorded by

A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease
Lucia Sessa, Simona Concilio, Jesús Fominaya, Daniela Eletto, Stefano Piotto, Xavier Busquets
Life Sciences.2023; 314: 121315. CrossRef
Serotonin reuptake transporter deficiency promotes liver steatosis and impairs intestinal barrier function in obese mice fed a Western‐style diet
Louisa Filipe Rosa, Eva Haasis, Annkathrin Knauss, Daria Guseva, Stephan C. Bischoff
Neurogastroenterology & Motility.2023;[Epub] CrossRef
Probiotics counteract hepatic steatosis caused by ketogenic diet and upregulate AMPK signaling in a model of infantile epilepsy
Chunlong Mu, Naghmeh Nikpoor, Thomas A. Tompkins, Jong M. Rho, Morris H. Scantlebury, Jane Shearer
eBioMedicine.2022; 76: 103838. CrossRef
Research Progresses for 5-Hydroxytryptamine in Lipid Metabolism
钰婷吴
Bioprocess.2022; 12(01): 1. CrossRef
Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease
Hang Yin, Anhua Shi, Junzi Wu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 2003. CrossRef
Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai
Disease Models & Mechanisms.2022;[Epub] CrossRef
Pancreatic Sirtuin 3 Deficiency Promotes Hepatic Steatosis by Enhancing 5-Hydroxytryptamine Synthesis in Mice With Diet-Induced Obesity
Xing Ming, Arthur C.K. Chung, Dandan Mao, Huanyi Cao, Baoqi Fan, Willy K.K. Wong, Chin Chung Ho, Heung Man Lee, Kristina Schoonjans, Johan Auwerx, Guy A. Rutter, Juliana C.N. Chan, Xiao Yu Tian, Alice P.S. Kong
Diabetes.2021; 70(1): 119. CrossRef
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease
Eun Jung Bae, Won Gun Choi, Haushabhau S. Pagire, Suvarna H. Pagire, Saravanan Parameswaran, Jun-Ho Choi, Jihyeon Yoon, Won-il Choi, Ji Hun Lee, Jin Sook Song, Myung Ae Bae, Mijin Kim, Jae-Han Jeon, In-Kyu Lee, Hail Kim, Jin Hee Ahn
Journal of Medicinal Chemistry.2021; 64(2): 1037. CrossRef
Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
Masayoshi Ko, Kenya Kamimura, Takashi Owaki, Takuro Nagoya, Norihiro Sakai, Itsuo Nagayama, Yusuke Niwa, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Ryosuke Inoue, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Shuji Terai
Disease Models & Mechanisms.2021;[Epub] CrossRef
Metabolic Disturbances in Rat Sublines with Constitutionally Altered Serotonin Homeostasis
Maja Kesić, Petra Baković, Ranko Stojković, Jasminka Štefulj, Lipa Čičin-Šain
International Journal of Molecular Sciences.2021; 22(10): 5400. CrossRef
Role of 5-HT degradation in acute liver injury induced by carbon tetrachloride
Yu-Xin Zhang, Chen Li, Xiu-Rui Liang, Jia-Qi Jin, Yi Zhang, Fan Xu, Jing Guan, Ying-Ying Ma, Xiao-Nan Ma, Run-Kun Liu, Ji-Hua Fu
European Journal of Pharmacology.2021; 908: 174355. CrossRef
Fluoxetine-induced hepatic lipid accumulation is linked to elevated serotonin production
Ahmed Ayyash, Alison C. Holloway
Canadian Journal of Physiology and Pharmacology.2021; 99(9): 983. CrossRef
Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease
Eleni Rebelos, Patricia Iozzo, Maria Angela Guzzardi, Maurizia Rossana Brunetto, Ferruccio Bonino
World Journal of Gastroenterology.2021; 27(30): 4999. CrossRef
Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance
Won Gun Choi, Wonsuk Choi, Tae Jung Oh, Hye-Na Cha, Inseon Hwang, Yun Kyung Lee, Seung Yeon Lee, Hyemi Shin, Ajin Lim, Dongryeol Ryu, Jae Myoung Suh, So-Young Park, Sung Hee Choi, Hail Kim
Journal of Clinical Investigation.2021;[Epub] CrossRef
Green tea and selenium-enriched green tea ameliorates non-alcoholic fatty liver disease through peripheral 5-hydroxytryptamine signals in high-fat diet-fed mice
Lin Zhang, Jia-Ying Xu, Ya-Fang Du, Zhang-Min Wang, Jian-Xiang Li, N. Ou-Yang, Yan Wang, Xue-Bin Yin, Li-Qiang Qin
International Food Research Journal.2021; 28(5): 996. CrossRef
Inhibition of serotonin synthesis: A novel therapeutic paradigm
Michael Bader
Pharmacology & Therapeutics.2020; 205: 107423. CrossRef
One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All
da Silva Robin P, Eudy Brandon J, Deminice Rafael
The Journal of Nutrition.2020; 150(5): 994. CrossRef
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT2A Antagonists for Nonalcoholic Fatty Liver Disease
Minhee Kim, Inseon Hwang, Haushabhau S. Pagire, Suvarna H. Pagire, Wonsuk Choi, Won Gun Choi, Jihyeon Yoon, Won Mi Lee, Jin Sook Song, Eun Kyung Yoo, Seung Mi Lee, Mi-jin Kim, Myung Ae Bae, Dooseop Kim, Heejong Lee, Eun-Young Lee, Jae-Han Jeon, In-Kyu Lee
Journal of Medicinal Chemistry.2020; 63(8): 4171. CrossRef
Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef
The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yijing Yu, Fitore Raka, Khosrow Adeli
Journal of Clinical Medicine.2019; 8(12): 2227. CrossRef
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
Julian M Yabut, Justin D Crane, Alexander E Green, Damien J Keating, Waliul I Khan, Gregory R Steinberg
Endocrine Reviews.2019; 40(4): 1092. CrossRef
Serotonin signals through a gut-liver axis to regulate hepatic steatosis
Wonsuk Choi, Jun Namkung, Inseon Hwang, Hyeongseok Kim, Ajin Lim, Hye Jung Park, Hye Won Lee, Kwang-Hyub Han, Seongyeol Park, Ji-Seon Jeong, Geul Bang, Young Hwan Kim, Vijay K. Yadav, Gerard Karsenty, Young Seok Ju, Chan Choi, Jae Myoung Suh, Jun Yong Par
Nature Communications.2018;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search